{"id":668,"date":"2020-11-27T05:50:34","date_gmt":"2020-11-27T05:50:34","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=668"},"modified":"2020-11-27T05:50:34","modified_gmt":"2020-11-27T05:50:34","slug":"21-nov-2020-anakinra-found-to-be-efficient-for-severe-covid-19-pneumonia-and-high-oxygen-requirement","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/21-nov-2020-anakinra-found-to-be-efficient-for-severe-covid-19-pneumonia-and-high-oxygen-requirement\/","title":{"rendered":"(21 Nov 2020) Anakinra- found to be efficient for severe COVID-19 pneumonia and high oxygen requirement"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.ijid.2020.11.149<\/p>\n<p class=\"\">A prospective, open-label, interventional study (ISRCTN74727214) in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were need for mechanical ventilation and in-hospital death.&nbsp; A total of 69 patients were included; 45 anakinra-treated and 24 historical controls. Need for mechanical ventilation occurred in 14 (31%) in the anakinra-treated group and 18 (75%) in the historical cohort (p &lt; 0.001). In-hospital death occurred in 13 (29%) in the anakinra-treated group and 11 (46%) in the historical cohort (p = 0.082). Successful weaning from supplemental oxygen to ambient air was attained in 25 (63%) in the anakinra-treated compared with 6 (27%) in the historical cohort (p = 0.008). Patients who received anakinra showed significant reduction in inflammatory biomarkers. In patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra could represent an effective treatment option and may confer clinical benefit.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study https:\/\/doi.org\/10.1016\/j.ijid.2020.11.149 A prospective, open-label, interventional study (ISRCTN74727214) in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/21-nov-2020-anakinra-found-to-be-efficient-for-severe-covid-19-pneumonia-and-high-oxygen-requirement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(21 Nov 2020) Anakinra- found to be efficient for severe COVID-19 pneumonia and high oxygen requirement&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[56,6,4],"tags":[57],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/668"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=668"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/668\/revisions"}],"predecessor-version":[{"id":688,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/668\/revisions\/688"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}